Combining FDA-approved Alzheimer's antibodies aducanumab and lecanemab with resveratrol and curcumin achieved 89-97% inhibition of amyloid-beta aggregation, compared to 50-71% for antibodies alone. The natural compounds appear to bind different regions of amyloid plaques than antibodies, creating synergistic effects that dramatically reduce toxic fibril formation while protecting neurons from damage. This represents a potentially transformative approach to Alzheimer's treatment, suggesting that pairing expensive monoclonal antibodies with affordable natural compounds could deliver superior therapeutic outcomes. The finding is particularly significant given the modest clinical benefits and high costs of current antibody monotherapies. However, this remains early-stage laboratory research using isolated proteins and mouse neurons. The challenge now lies in translating these impressive in vitro results to human clinical trials, where bioavailability of curcumin and resveratrol, proper dosing ratios, and real-world effectiveness must be validated. If successful, such combination strategies could revolutionize Alzheimer's treatment by making therapies both more effective and accessible.